Clinical trials: First Line Treatment
Non-Small Cell Lung Cancer
A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Part 1 is complete. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, phase 2 segment that will commence upon identification of the maximum tolerated dose in part 1.
- Trial name
- NCT00534027
- Testing
- AMG 655
- Volunteers
- 172 people
- Sponsor
- Amgen
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
This 2-arm study was designed to evaluate the efficacy and safety of 2 treatment regimens of Xeloda and Avastin, with either irinotecan or oxaliplatin administered for the first 12 cycles, as first line treatment in patients with…
- Trial name
- NCT00642603
- Testing
- capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin
- Where
- 76 sites in United States
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Stomach Cancer
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together.
- Trial name
- NCT05427383
- Testing
- KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Shanghai JMT-Bio Inc.
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
This randomized phase II trial is studying how well giving docetaxel together with either cetuximab or bortezomib works as first-line therapy in treating patients with stage III or stage IV non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Malignant Pleural Effusion
- Trial name
- NCT00118183
- Testing
- docetaxel, cetuximab, bortezomib
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer
This is an open-label, multicenter, randomized parallel-group phase 2 study evaluating the efficacy and safety of Fruquintinib alternating with Bevacizumab plus Capecitabine versus Bevacizumab plus Capecitabine as maintenance…
- Trial name
- NCT05659290
- Testing
- Fruquintinib alternating with Bevacizumab plus Capecitabine, Bevacizumab plus Capecitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cholestasis, Progressive Familial Intrahepatic 3
Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION
Cholangiocarcinoma (CCK) is a rare tumor (2000 new cases/year in France) with very poor prognosis (overall survival < 3% at 5 years).
- Trial name
- CHOLANGIOSIR (NCT01383746)
- Testing
- Yttrium microsphere injection
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00423696
- Testing
- bevacizumab, capecitabine, fluorouracil
- Where
- 15 sites in France
- Volunteers
- 145 people
- Sponsor
- UNICANCER
Metastatic Soft Tissue Sarcoma
Phase II Study of Regorafenib as Maintenance Therapy
Multicenter double-blind placebo-controlled randomized Phase II study comparing regorafenib® to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas experiencing stable disease or response after 6…
- Trial name
- EREMISS (NCT03793361)
- Testing
- Regorafenib
- Where
- 20 sites in France
- Volunteers
- 127 people
- Sponsor
- Centre Oscar Lambret
Differentiated Thyroid Cancer (DTC), Poorly Differentiated Thyroid Cancer
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Phase II, non-randomized, open-label study to determine the efficacy of cabozantinib as a firstline treatment for patients with differentiated thyroid cancer (DTC). Subjects will receive drug at a starting dose of 60mg PO QD.
- Trial name
- NCT02041260
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Thomas Jefferson University
Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This phase II trial studies how well first-line treatment of bevacizumab, carboplatin, and paclitaxel work in treating participants with stage III- IV ovarian, primary peritoneal and fallopian tube cancer.
- Conditions
- Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
- Trial name
- NCT01097746
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Pancreas, Locally Advanced
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
This study is a phase 2, multicenter, randomized, double-blind, active placebo-controlled trial of AMG 479 or placebo in combination with gemcitabine as first-line therapy for locally advanced unresectable adenocarinoma of the…
- Conditions
- Adenocarcinoma of the Pancreas, Locally Advanced, Unresectable
- Trial name
- NCT01318642
- Testing
- Gemcitabine, AMG 479
- Where
- 35 sites in United States, Austria and 11 more
- Volunteers
- 10 people
- Sponsor
- NantBioScience, Inc.
Phimosis
Mild Versus Potent Corticosteroids as Treatment for Phimosis in Children
Topical steroids are used as treatment for non-retractile foreskin in children for decades, but, there are disagreement among physicians about the optimum potency of the agent used.
- Trial name
- TopSteP (NCT00933023)
- Testing
- hydrocortisone, Betamethasone
- Where
- United Kingdom
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC)…
- Conditions
- Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
- Trial name
- NCT05363280
- Testing
- AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
- Where
- 7 sites in United States, Spain
- Volunteers
- 80 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Non Small Cell Lung Cancer, Brain Metastases, Adult
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
This is an open-label, non-randomised, phase II, multicenter clinical trial. 71 stage IV or recurrent, non-small cell lung cancer patients with synchronous brain metastases will be enrolled in this trial to evaluate the efficacy…
- Conditions
- Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer
- Trial name
- NIVIPI-Brain (NCT05012254)
- Testing
- Ipilimumab, Nivolumab, Carboplatin
- Where
- 18 sites in Spain
- Volunteers
- 71 people
- Sponsor
- Fundación GECP
Small Cell Lung Carcinoma
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)
- Trial name
- GUIDANCE (NCT06419179)
- Testing
- Durvalumab, Olaparib
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- University of Cologne
Advanced Gastric Carcinoma
A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma
Open label single arm phase II study of Pemetrexed plus Oxaliplatin in patients with advanced gastric carcinoma not previously treated with palliative chemotherapy. 43 Patients will be enrolled in this local trial.
- Trial name
- NCT00192088
- Testing
- pemetrexed, oxaliplatin
- Where
- 13 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Advanced Esophageal Squamous Cell Carcinoma
Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy for patients with advanced esophageal squamous cell carcinoma (Answer): A randomized two-arm clinical study.
- Trial name
- ANSWER (NCT05214222)
- Testing
- Anlotinib/Penpulimab/Chemotherapy, Penpulimab/Chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Breast Cancer, Cancer of Breast
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Multiple neoadjuvant endocrine trials demonstrate that women with good prognosis tumors can be identified. These trials have also demonstrated that there are not adverse effects on overall outcome if women are treated with…
- Conditions
- Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
- Trial name
- NCT02476786
- Testing
- FACT-B, Goserelin, Anastrozole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B
Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
The aim of this multicenter, non-randomized, cluster controlled trial study is to evaluate the impact of a geriatric-guided approach with a pro-active rehabilitative/nutritional plan for elderly unfit/frail DLBCL patients…
- Trial name
- NCT07476105
- Testing
- Geriatric-guided supportive care, Conventional supportive care
- Where
- 24 sites in Italy
- Volunteers
- 170 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Advanced Biliary Tract Cancer(BTC)
A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer
Primary Objective: To evaluate disease control rate (DCR) of S-1 in combination with gemcitabine in patients with advanced biliary tract cancer Secondary Objectives: To evaluate overall response rate (ORR) To evaluate…
- Trial name
- NCT02425137
- Testing
- S-1/Gemcitabine
- Where
- 4 sites in Taiwan
- Volunteers
- 51 people
- Sponsor
- TTY Biopharm
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.